Cargando…
Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820818/ https://www.ncbi.nlm.nih.gov/pubmed/33482867 http://dx.doi.org/10.1186/s13054-021-03470-3 |
| _version_ | 1783639291535032320 |
|---|---|
| author | Hariri, Geoffroy Urbina, Tomas Mazerand, Sandie Bige, Naike Baudel, Jean-Luc Ait-Oufella, Hafid |
| author_facet | Hariri, Geoffroy Urbina, Tomas Mazerand, Sandie Bige, Naike Baudel, Jean-Luc Ait-Oufella, Hafid |
| author_sort | Hariri, Geoffroy |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7820818 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78208182021-01-22 Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients Hariri, Geoffroy Urbina, Tomas Mazerand, Sandie Bige, Naike Baudel, Jean-Luc Ait-Oufella, Hafid Crit Care Research Letter BioMed Central 2021-01-22 /pmc/articles/PMC7820818/ /pubmed/33482867 http://dx.doi.org/10.1186/s13054-021-03470-3 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Research Letter Hariri, Geoffroy Urbina, Tomas Mazerand, Sandie Bige, Naike Baudel, Jean-Luc Ait-Oufella, Hafid Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients |
| title | Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients |
| title_full | Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients |
| title_fullStr | Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients |
| title_full_unstemmed | Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients |
| title_short | Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients |
| title_sort | rate control in atrial fibrillation using landiolol is safe in critically ill covid-19 patients |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820818/ https://www.ncbi.nlm.nih.gov/pubmed/33482867 http://dx.doi.org/10.1186/s13054-021-03470-3 |
| work_keys_str_mv | AT haririgeoffroy ratecontrolinatrialfibrillationusinglandiololissafeincriticallyillcovid19patients AT urbinatomas ratecontrolinatrialfibrillationusinglandiololissafeincriticallyillcovid19patients AT mazerandsandie ratecontrolinatrialfibrillationusinglandiololissafeincriticallyillcovid19patients AT bigenaike ratecontrolinatrialfibrillationusinglandiololissafeincriticallyillcovid19patients AT baudeljeanluc ratecontrolinatrialfibrillationusinglandiololissafeincriticallyillcovid19patients AT aitoufellahafid ratecontrolinatrialfibrillationusinglandiololissafeincriticallyillcovid19patients |